{
  "Protocol Info": {
    "Client Name": "Sanofi-Aventis Recherche & Développement",
    "Most Recent Protocol Version Utilized to Generate Requirements": "Version 10 (07-SEP-2023)",
    "Open Label": "Yes",
    "Protocol": "EFC17360",
    "Protocol Description": "A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)",
    "Pulse Version": null,
    "Study Blind Type": "Double-blind"
  },
  "Schema": {
    "Description": "The study design is represented in a diagram showing the different phases of the clinical trial. It includes a screening period, a double-blind period (PAP), an open-label period (OLP), and a long-term extension (LTE) period. Participants are randomized to receive either rilzabrutinib or placebo during the PAP. All participants receive rilzabrutinib during the OLP and LTE. The diagram also indicates follow-up periods after each phase.",
    "Example": "For example, a participant starts with a 4-week screening, then enters a 24-week double-blind period where they might receive either rilzabrutinib or placebo. After this, they enter a 28-week open-label period where all receive rilzabrutinib, followed by a long-term extension if they meet certain criteria.",
    "KeyElements": [
      "Screening period: 4 weeks",
      "Double-blind Period (PAP): Week 1 - Week 24",
      "Open-Label Period (OLP): Week 24 - Week 52",
      "Long-Term Extension Period (LTE): Week 52 - End of LTE",
      "Randomization: 2:1 ratio of rilzabrutinib to placebo",
      "Follow-up periods after each phase"
    ],
    "SchemaName": "Graphical study design",
    "SchemaType": "Diagram",
    "SectionReference": "1.2 SCHEMA"
  },
  "Treatment and Kit Types": [
    { "KitType": "Investigational Medicinal Product Kit", "TreatmentArm": "Rilzabrutinib", "TreatmentName": "Rilzabrutinib" },
    { "KitType": "Placebo Kit", "TreatmentArm": "Placebo", "TreatmentName": "Placebo" }
  ],
  "Rand Details": {
    "Randomization": {
      "AllocationRatio": "2:1",
      "Example": "Participants are randomly assigned to either the rilzabrutinib group or the placebo group in a 2:1 ratio. For example, if there are 90 participants, 60 will receive rilzabrutinib and 30 will receive placebo.",
      "Method": "centralized randomization via IRT"
    },
    "Stratification": [
      { "Factor": "Prior rituximab use", "Levels": ["Yes", "No"] },
      { "Factor": "Severity of anemia at baseline", "Levels": ["Hb <8 g/dL", "Hb ≥8 g/dL"] }
    ]
  },
  "Dispensation Logic": 
  [
    { "KitType": null, "Quantity": null, "TreatmentArm": null, "VisitName": "Screening" },
    { "KitType": "Rilzabrutinib Kit", "Quantity": "1 tablet BID", "TreatmentArm": "Arm A1", "VisitName": "Cycle 1 Day 1" },
    { "KitType": "Placebo Kit", "Quantity": "1 tablet BID", "TreatmentArm": "Arm B", "VisitName": "Cycle 1 Day 1" }    ,
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 8"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 8"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 15"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 29"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 29"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 43"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 57"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 71"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 71"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 85"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 99"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 113"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 113"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 127"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 141"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 155"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 155"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 169"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 183"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 183"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 197"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 211"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 225"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 225"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 239"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 253"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 267"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 267"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 281"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 295"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 309"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 309"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 323"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 337"
    },
    {
      "KitType": "Rilzabrutinib Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm A1",
      "VisitName": "Cycle 1 Day 351"
    },
    {
      "KitType": "Placebo Kit",
      "Quantity": "1 tablet BID",
      "TreatmentArm": "Arm B",
      "VisitName": "Cycle 1 Day 351"
    },
    {
      "KitType": null,
      "Quantity": null,
      "TreatmentArm": null,
      "VisitName": "Cycle 1 Day 365"
    }
  ],
  "Dosing Logic": [
    { "DosingDetails": "400 mg BID", "KitType": "Rilzabrutinib", "Quantity": null, "TreatmentArm": "Arm A", "VisitName": "Day 1" },
    { "DosingDetails": "0 mg BID", "KitType": "Placebo", "Quantity": null, "TreatmentArm": "Arm B", "VisitName": "Day 1" },
    { "DosingDetails": "400 mg BID", "KitType": "Rilzabrutinib", "Quantity": null, "TreatmentArm": "All", "VisitName": "Week 24" },
    { "DosingDetails": "400 mg BID", "KitType": "Rilzabrutinib", "Quantity": null, "TreatmentArm": "All", "VisitName": "Week 52" }
  ],
  "Titration Logic": { "Titration / Dose Modification": "No" },
  "Visit Schedule": [
    { "Visit": "Screening", "VisitWeek": "Week -4", "VisitType": "Screening", "VisitCalculatedFrom": "TBC-Client", "KitType": "TBC-Client" },
    {
      "Visit": "Day 1",
      "VisitWeek": "Week 0",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "TBC-Client",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 8",
      "VisitWeek": "Week 1",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 1 day from Day 1",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 15",
      "VisitWeek": "Week 2",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 8",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 29",
      "VisitWeek": "Week 4",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 15",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 43",
      "VisitWeek": "Week 6",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 29",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 57",
      "VisitWeek": "Week 8",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 43",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 71",
      "VisitWeek": "Week 10",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 57",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 85",
      "VisitWeek": "Week 12",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 71",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 99",
      "VisitWeek": "Week 14",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 85",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 113",
      "VisitWeek": "Week 16",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 99",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 127",
      "VisitWeek": "Week 18",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 113",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 141",
      "VisitWeek": "Week 20",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 127",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 155",
      "VisitWeek": "Week 22",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 141",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Day 169",
      "VisitWeek": "Week 24",
      "VisitType": "Treatment",
      "VisitCalculatedFrom": "± 3 days from Day 155",
      "KitType": "Blinded Study Intervention Kit"
    },
    {
      "Visit": "Follow-up",
      "VisitWeek": "Week 26",
      "VisitType": "Follow-up",
      "VisitCalculatedFrom": "14 days after last IMP dose",
      "KitType": "TBC-Client"
    },
    {
      "Visit": "Day 183",
      "VisitWeek": "Week 26",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 169",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 197",
      "VisitWeek": "Week 28",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 183",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 211",
      "VisitWeek": "Week 30",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 197",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 225",
      "VisitWeek": "Week 32",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 211",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 239",
      "VisitWeek": "Week 34",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 225",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 253",
      "VisitWeek": "Week 36",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 239",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 267",
      "VisitWeek": "Week 38",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 253",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 281",
      "VisitWeek": "Week 40",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 267",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 295",
      "VisitWeek": "Week 42",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 281",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 309",
      "VisitWeek": "Week 44",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 295",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 323",
      "VisitWeek": "Week 46",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 309",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 337",
      "VisitWeek": "Week 48",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 323",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 351",
      "VisitWeek": "Week 50",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 337",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Day 365",
      "VisitWeek": "Week 52",
      "VisitType": "Open-Label Period",
      "VisitCalculatedFrom": "± 3 days from Day 351",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "End of Study",
      "VisitWeek": "Week 54",
      "VisitType": "Follow-up",
      "VisitCalculatedFrom": "14 days post-last dose",
      "KitType": "TBC-Client"
    },
    {
      "Visit": "Long-Term Extension",
      "VisitWeek": "Week 56 to Week 100",
      "VisitType": "Long-Term Extension",
      "VisitCalculatedFrom": "Clinic Visits every 28 days for the first 12 months",
      "KitType": "Open-Label Study Intervention Kit"
    },
    {
      "Visit": "Long-Term Extension",
      "VisitWeek": "Week 112 onwards",
      "VisitType": "Long-Term Extension",
      "VisitCalculatedFrom": "Clinic Visits every 3 months after 12 months of LTE",
      "KitType": "Open-Label Study Intervention Kit"
    }
  ],
  "Cohort": {
    "Cohorts": [
      { "Cohort": "Double-blind Period (PAP)", "CohortType": "Phase 3" },
      { "Cohort": "Open-Label Period (OLP)", "CohortType": "Open-label" },
      { "Cohort": "Long-Term Extension (LTE)", "CohortType": "Long-term extension" }
    ],
    "TotalCohorts": 3
  },
  "Screen Failure & Rescreening logic": {
    "NewScreeningNumber": "string or TBC-Client",
    "ReRescreeningPolicy": "TBC-Client",
    "RescreeningPolicy": "Rescreened participants should be assigned a new participant number for every screening/rescreening event. A participant may be rescreened upon approval of the Medical Monitor. In this situation, the rescreened participant should sign a new ICF if the rescreening exceeds 45 days from the previous ICF signature date.",
    "ScreenFailureApplicable": "Yes",
    "ScreenFailureReasons": ["string or TBC-Client"]
  }

}